featured
IASLC WCLC Virtual: KEYNOTE-10 5-Year Update Demonstrates Durable Benefits of Second-Line Pembrolizumab in Non-Small Cell Lung Cancer
Benefits are particularly remarkable in patients with high PD-L1 expression
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.